{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T10:45:32Z","timestamp":1789469132302,"version":"build-2803163510"},"reference-count":92,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T00:00:00Z","timestamp":1784851200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T00:00:00Z","timestamp":1786579200000},"content-version":"vor","delay-in-days":20,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key R&D Program of China","doi-asserted-by":"crossref","award":["2022YFC2502700"],"award-info":[{"award-number":["2022YFC2502700"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81970138"],"award-info":[{"award-number":["81970138"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82470174"],"award-info":[{"award-number":["82470174"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Jiangsu Province Natural Science Foundation of China","award":["BK20221235"],"award-info":[{"award-number":["BK20221235"]}]},{"name":"Jiangsu Province \u201c333\u201d Project, Social Development Project of the Science and Technology Department of Jiangsu","award":["BE2021649"],"award-info":[{"award-number":["BE2021649"]}]},{"name":"Boxi Clinical Research Project","award":["BXLC008"],"award-info":[{"award-number":["BXLC008"]}]},{"name":"Boxi Clinical Research Project","award":["BXLC2024009"],"award-info":[{"award-number":["BXLC2024009"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"DOI":"10.1007\/s00277-026-07191-x","type":"journal-article","created":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T09:34:05Z","timestamp":1784885645000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Therapeutic Advances in Adult B-cell Acute Lymphoblastic Leukemia with KMT2A Rearrangements"],"prefix":"10.1007","volume":"105","author":[{"given":"Shen-Hao","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ai-Ni","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui-Ying","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai-Wen","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng-Li","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hai-Ping","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,24]]},"reference":[{"key":"7191_CR1","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1016\/S0140-6736(19)33018-1","volume":"395","author":"F Malard","year":"2020","unstructured":"Malard F, Mohty M (2020) Acute lymphoblastic leukaemia. Lancet 395:1146\u20131162. https:\/\/doi.org\/10.1016\/S0140-6736(19)33018-1","journal-title":"Lancet"},{"key":"7191_CR2","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1182\/blood.2023022919","volume":"145","author":"M Passet","year":"2025","unstructured":"Passet M, Kim R, Clappier E (2025) Genetic subtypes of B-cell acute lymphoblastic leukemia in adults. Blood 145:1451\u20131463. https:\/\/doi.org\/10.1182\/blood.2023022919","journal-title":"Blood"},{"key":"7191_CR3","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1038\/leu.2017.213","volume":"32","author":"C Meyer","year":"2018","unstructured":"Meyer C, Burmeister T, Gr\u00f6ger D et al (2018) The MLL recombinome of acute leukemias in 2017. Leukemia 32:273\u2013284. https:\/\/doi.org\/10.1038\/leu.2017.213","journal-title":"Leukemia"},{"key":"7191_CR4","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s11899-020-00582-5","volume":"15","author":"F El Chaer","year":"2020","unstructured":"El Chaer F, Keng M, Ballen KK (2020) MLL-rearranged acute lymphoblastic leukemia. Curr Hematol Malig Rep 15:83\u201389. https:\/\/doi.org\/10.1007\/s11899-020-00582-5","journal-title":"Curr Hematol Malig Rep"},{"key":"7191_CR5","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1002\/cncr.30376","volume":"123","author":"GC Issa","year":"2017","unstructured":"Issa GC, Kantarjian HM, Yin CC et al (2017) Prognostic impact of pretreatment cytogenetics in adult Philadelphia chromosome-negative acute lymphoblastic leukemia in the era of minimal residual disease. Cancer 123:459\u2013467. https:\/\/doi.org\/10.1002\/cncr.30376","journal-title":"Cancer"},{"key":"7191_CR6","doi-asserted-by":"publisher","first-page":"5415","DOI":"10.1182\/bloodadvances.2021004580","volume":"5","author":"G Richard-Carpentier","year":"2021","unstructured":"Richard-Carpentier G, Kantarjian HM, Tang G et al (2021) Outcomes of acute lymphoblastic leukemia with KMT2A (MLL) rearrangement: the MD Anderson experience. Blood Adv 5:5415\u20135419. https:\/\/doi.org\/10.1182\/bloodadvances.2021004580","journal-title":"Blood Adv"},{"key":"7191_CR7","doi-asserted-by":"publisher","first-page":"945","DOI":"10.3324\/haematol.2012.081877","volume":"98","author":"DI Marks","year":"2013","unstructured":"Marks DI, Moorman AV, Chilton L et al (2013) The clinical characteristics, therapy and outcome of 85 adults with acute lymphoblastic leukemia and t(4;11)(q21;q23)\/MLL-AFF1 prospectively treated in the UKALLXII\/ECOG2993 trial. Haematologica 98:945\u2013952. https:\/\/doi.org\/10.3324\/haematol.2012.081877","journal-title":"Haematologica"},{"key":"7191_CR8","doi-asserted-by":"publisher","first-page":"1806","DOI":"10.1182\/blood.2023021501","volume":"142","author":"R Kim","year":"2023","unstructured":"Kim R, Bergugnat H, Pastoret C et al (2023) Genetic alterations and MRD refine risk assessment for KMT2A-rearranged B-cell precursor ALL in adults: a GRAALL study. Blood 142:1806\u20131817. https:\/\/doi.org\/10.1182\/blood.2023021501","journal-title":"Blood"},{"key":"7191_CR9","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1080\/10428194.2016.1177182","volume":"58","author":"C Motll\u00f3","year":"2017","unstructured":"Motll\u00f3 C, Ribera J-M, Morgades M et al (2017) Frequency and prognostic significance of t(v;11q23)\/KMT2A rearrangements in adult patients with acute lymphoblastic leukemia treated with risk-adapted protocols. Leuk Lymphoma 58:145\u2013152. https:\/\/doi.org\/10.1080\/10428194.2016.1177182","journal-title":"Leuk Lymphoma"},{"key":"7191_CR10","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26253","author":"A Piciocchi","year":"2021","unstructured":"Piciocchi A, Messina M, Elia L et al (2021) Prognostic impact of KMT2A-AFF1-positivity in 926 BCR-ABL1-negative B-lineage acute lymphoblastic leukemia patients treated in GIMEMA clinical trials since 1996. Am J Hematol. https:\/\/doi.org\/10.1002\/ajh.26253","journal-title":"Am J Hematol"},{"key":"7191_CR11","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1038\/s41375-021-01135-2","volume":"35","author":"J Esteve","year":"2021","unstructured":"Esteve J, Giebel S, Labopin M et al (2021) Allogeneic hematopoietic stem cell transplantation for adult patients with t(4;11)(q21;q23) KMT2A\/AFF1 B-cell precursor acute lymphoblastic leukemia in first complete remission: impact of pretransplant measurable residual disease (MRD) status. An analysis from the Acute Leukemia Working Party of the EBMT. Leukemia 35:2232\u20132242. https:\/\/doi.org\/10.1038\/s41375-021-01135-2","journal-title":"Leukemia"},{"key":"7191_CR12","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.70326","volume":"13","author":"L Yin","year":"2024","unstructured":"Yin L, Wan L, Zhang Y et al (2024) Recent developments and evolving therapeutic strategies in KMT2A-rearranged acute leukemia. Cancer Med 13:e70326. https:\/\/doi.org\/10.1002\/cam4.70326","journal-title":"Cancer Med"},{"key":"7191_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejcped.2024.100204","volume":"4","author":"RS Kotecha","year":"2024","unstructured":"Kotecha RS, Pieters R, Stutterheim J (2024) KMT2A-rearranged acute lymphoblastic leukaemia. EJC Paediatric Oncology 4:100204. https:\/\/doi.org\/10.1016\/j.ejcped.2024.100204","journal-title":"EJC Paediatric Oncology"},{"key":"7191_CR14","unstructured":"National Comprehensive Cancer Network (NCCN) (2025) Acute Lymphoblastic Leukemia"},{"key":"7191_CR15","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1056\/NEJMoa1609783","volume":"376","author":"H Kantarjian","year":"2017","unstructured":"Kantarjian H, Stein A, G\u00f6kbuget N et al (2017) Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia. N Engl J Med 376:836\u2013847. https:\/\/doi.org\/10.1056\/NEJMoa1609783","journal-title":"N Engl J Med"},{"key":"7191_CR16","doi-asserted-by":"publisher","first-page":"e878","DOI":"10.1016\/S2352-3026(22)00285-X","volume":"9","author":"E Jabbour","year":"2022","unstructured":"Jabbour E, Short NJ, Jain N et al (2022) Hyper-CVAD and sequential blinatumomab for newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: a single-arm, single-centre, phase 2 trial. Lancet Haematol 9:e878\u2013e885. https:\/\/doi.org\/10.1016\/S2352-3026(22)00285-X","journal-title":"Lancet Haematol"},{"key":"7191_CR17","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1056\/NEJMoa2312948","volume":"391","author":"MR Litzow","year":"2024","unstructured":"Litzow MR, Sun Z, Mattison RJ et al (2024) Blinatumomab for MRD-Negative Acute Lymphoblastic Leukemia in Adults. N Engl J Med 391:320\u2013333. https:\/\/doi.org\/10.1056\/NEJMoa2312948","journal-title":"N Engl J Med"},{"key":"7191_CR18","unstructured":"Dinner S, Paietta ZSE, Mattison R, Roberts K, Zhang Y, Racevskis J, Lazarus H, Rowe J, Arber D, Wieduwilt M, Liedtke M, Bergeron J, Wood B, Zhao Y, Wu G, Chang T-C, Zhang W, Pratz K Noelle Frey, Steven Gore, Bhavana Bhatnagar, Ehab Atallah, Geoffrey Uy, Deepa Jeyakumar, Tara Lin, Cheryl Willman, Nikolai Podoltsev, Daniel DeAngelo, Shejal Patel, Michelle Elliott, Anjali Advani, Dimitrios Tzachanis, Pankit Vachhani, Rupali Roy Bhave, Elad Sharon, Richard Little, Harry Erba, Richard Stone, Charles Mullighan, Martin Tallman, Selina Luger, Mark Litzow Addition of Blinatumomab to Consolidation Therapy for Younger Adults (BCR:ABL1-Negative B-Acute Lymphoblastic Leukemia (All) on the Ecog-Acrin E1910 Phase III Trial"},{"key":"7191_CR19","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1182\/blood-2022-159397","volume":"140","author":"N Boissel","year":"2022","unstructured":"Boissel N, Huguet F, Leguay T et al (2022) Blinatumomab during Consolidation in High-Risk Philadelphia Chromosome (Ph)-Negative B-Cell Precursor (BCP) Acute Lymphoblastic Leukemia (ALL) Adult Patients: A Two-Cohort Comparison within the Graall-2014\/B Study. Blood 140:507\u2013509. https:\/\/doi.org\/10.1182\/blood-2022-159397","journal-title":"Blood"},{"key":"7191_CR20","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-024-01597-8","volume":"17","author":"J Lu","year":"2024","unstructured":"Lu J, Qiu H, Wang Y et al (2024) Reduced-dose chemotherapy and blinatumomab as induction treatment for newly diagnosed Ph-negative B-cell precursor acute lymphoblastic leukemia: a phase 2 trial. J Hematol Oncol 17:79. https:\/\/doi.org\/10.1186\/s13045-024-01597-8","journal-title":"J Hematol Oncol"},{"key":"7191_CR21","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1056\/NEJMoa2214171","volume":"388","author":"IM Van Der Sluis","year":"2023","unstructured":"Van Der Sluis IM, De Lorenzo P, Kotecha RS et al (2023) Blinatumomab Added to Chemotherapy in Infant Lymphoblastic Leukemia. N Engl J Med 388:1572\u20131581. https:\/\/doi.org\/10.1056\/NEJMoa2214171","journal-title":"N Engl J Med"},{"key":"7191_CR22","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1200\/JCO-25-01806","volume":"44","author":"M Vieira Martins","year":"2026","unstructured":"Vieira Martins M, de Lorenzo P, Kotecha RS et al (2026) Sustained Benefit of Blinatumomab in Infants With KMT2A-Rearranged ALL: Long-Term Outcomes, Toxicity, and Pharmacokinetics. J Clin Oncol 44:370\u2013374. https:\/\/doi.org\/10.1200\/JCO-25-01806","journal-title":"J Clin Oncol"},{"key":"7191_CR23","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1182\/blood.2024024517","volume":"145","author":"AJ Lamble","year":"2025","unstructured":"Lamble AJ, Kovach AE, Shah NN (2025) How I treat postimmunotherapy relapsed B-ALL. Blood 145:64\u201374. https:\/\/doi.org\/10.1182\/blood.2024024517","journal-title":"Blood"},{"key":"7191_CR24","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1182\/blood.2024026655","volume":"146","author":"SK Silbert","year":"2025","unstructured":"Silbert SK, Rankin AW, Hoang CN et al (2025) Project EVOLVE: an international analysis of postimmunotherapy lineage switch, an emergent form of relapse in leukemia. Blood 146:437\u2013455. https:\/\/doi.org\/10.1182\/blood.2024026655","journal-title":"Blood"},{"key":"7191_CR25","doi-asserted-by":"publisher","first-page":"e607","DOI":"10.1038\/bcj.2017.89","volume":"7","author":"CL Haddox","year":"2017","unstructured":"Haddox CL, Mangaonkar AA, Chen D et al (2017) Blinatumomab-induced lineage switch of B-ALL with t(4:11)(q21;q23) KMT2A\/AFF1 into an aggressive AML: pre- and post-switch phenotypic, cytogenetic and molecular analysis. Blood Cancer J 7:e607. https:\/\/doi.org\/10.1038\/bcj.2017.89","journal-title":"Blood Cancer J"},{"key":"7191_CR26","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1056\/NEJMoa1509277","volume":"375","author":"HM Kantarjian","year":"2016","unstructured":"Kantarjian HM, DeAngelo DJ, Stelljes M et al (2016) Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia. N Engl J Med 375:740\u2013753. https:\/\/doi.org\/10.1056\/NEJMoa1509277","journal-title":"N Engl J Med"},{"key":"7191_CR27","doi-asserted-by":"publisher","first-page":"3226","DOI":"10.1182\/bloodadvances.2023012430","volume":"8","author":"Y Zhao","year":"2024","unstructured":"Zhao Y, Laird AD, Roberts KG et al (2024) Association of leukemic molecular profile with efficacy of inotuzumab ozogamicin in adults with relapsed\/refractory ALL. Blood Adv 8:3226\u20133236. https:\/\/doi.org\/10.1182\/bloodadvances.2023012430","journal-title":"Blood Adv"},{"key":"7191_CR28","doi-asserted-by":"publisher","first-page":"2742","DOI":"10.1158\/1078-0432.CCR-20-2399","volume":"27","author":"HM Kantarjian","year":"2021","unstructured":"Kantarjian HM, Stock W, Cassaday RD et al (2021) Inotuzumab Ozogamicin for Relapsed\/Refractory Acute Lymphoblastic Leukemia in the INO-VATE Trial: CD22 Pharmacodynamics, Efficacy, and Safety by Baseline CD22. Clin Cancer Res 27:2742\u20132754. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-2399","journal-title":"Clin Cancer Res"},{"key":"7191_CR29","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1002\/pbc.25410","volume":"62","author":"NN Shah","year":"2015","unstructured":"Shah NN, Stetler-Stevenson M, Yuan CM et al (2015) Characterization of CD22 Expression in Acute Lymphoblastic Leukemia. Pediatr Blood Cancer 62:964\u2013969. https:\/\/doi.org\/10.1002\/pbc.25410","journal-title":"Pediatr Blood Cancer"},{"key":"7191_CR30","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1038\/leu.2011.206","volume":"26","author":"JF de Vries","year":"2012","unstructured":"de Vries JF, Zwaan CM, De Bie M et al (2012) The novel calicheamicin-conjugated CD22 antibody inotuzumab ozogamicin (CMC-544) effectively kills primary pediatric acute lymphoblastic leukemia cells. Leukemia 26:255\u2013264. https:\/\/doi.org\/10.1038\/leu.2011.206","journal-title":"Leukemia"},{"key":"7191_CR31","doi-asserted-by":"publisher","first-page":"e19017","DOI":"10.1200\/JCO.2023.41.16_suppl.e19017","volume":"41","author":"NJ Short","year":"2023","unstructured":"Short NJ, Jabbour E, Jain N et al (2023) A phase II study of hyper-CVAD with blinatumomab (blina) and inotuzumab ozogamicin (INO) for newly diagnosed Philadelphia chromosome (Ph)\u2013negative B-cell acute lymphoblastic leukemia (ALL). JCO 41:e19017\u2013e19017. https:\/\/doi.org\/10.1200\/JCO.2023.41.16_suppl.e19017","journal-title":"JCO"},{"key":"7191_CR32","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1182\/blood-2023-181379","volume":"142","author":"J Senapati","year":"2023","unstructured":"Senapati J, Jabbour E, Short NJ et al (2023) Impact of High-Risk Cytogenetics (HR-CTG) on the Outcome of Newly Diagnosed Adult Patients with Philadelphia Negative B-Cell Acute Lymphoblastic Leukemia (B-ALL) Treated with Frontline Blinatumomab (Blina) and\/or Inotuzumab Ozogamicin (Ino) Containing Hypercvad (HCVAD) Therapy. Blood 142:1500\u20131500. https:\/\/doi.org\/10.1182\/blood-2023-181379","journal-title":"Blood"},{"key":"7191_CR33","doi-asserted-by":"publisher","first-page":"4327","DOI":"10.1200\/JCO.24.00490","volume":"42","author":"P Chevallier","year":"2024","unstructured":"Chevallier P, Leguay T, Delord M et al (2024) Inotuzumab Ozogamicin and Low-Intensity Chemotherapy in Older Patients With Newly Diagnosed CD22+ Philadelphia Chromosome\u2013Negative B-Cell Precursor Acute Lymphoblastic Leukemia. JCO 42:4327\u20134341. https:\/\/doi.org\/10.1200\/JCO.24.00490","journal-title":"JCO"},{"key":"7191_CR34","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1182\/blood-2024-208742","volume":"144","author":"J Senapati","year":"2024","unstructured":"Senapati J, Jabbour E, Short NJ et al (2024) Chemotherapy Free Regimen of Inotuzumab Ozogamicin and Blinatumomab in Frontline Therapy of Older Patients with Philadelphia Negative B-Cell Acute Lymphoblastic Leukemia. Blood 144:1442\u20131442. https:\/\/doi.org\/10.1182\/blood-2024-208742","journal-title":"Blood"},{"key":"7191_CR35","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/S0140-6736(21)01222-8","volume":"398","author":"BD Shah","year":"2021","unstructured":"Shah BD, Ghobadi A, Oluwole OO et al (2021) KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study. Lancet 398:491\u2013502. https:\/\/doi.org\/10.1016\/S0140-6736(21)01222-8","journal-title":"Lancet"},{"key":"7191_CR36","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1038\/s41375-025-02532-7","volume":"39","author":"BD Shah","year":"2025","unstructured":"Shah BD, Cassaday RD, Park JH et al (2025) Three-year analysis of adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with brexucabtagene autoleucel in ZUMA-3. Leukemia 39:1058\u20131068. https:\/\/doi.org\/10.1038\/s41375-025-02532-7","journal-title":"Leukemia"},{"key":"7191_CR37","doi-asserted-by":"publisher","first-page":"3365","DOI":"10.1182\/blood-2025-3365","volume":"146","author":"J Leonard","year":"2025","unstructured":"Leonard J, Ladha A, Faramand R et al (2025) KMT2Ar, but not other high-risk genetics, adversely impacts outcomes in adult patients with relapsed\/refractory (R\/R) Philadelphia chromosome negative B-cell acute lymphoblastic leukemia (B-ALL) treated with brexucabtagene autoleucel (Brexu-cel). Blood 146:3365. https:\/\/doi.org\/10.1182\/blood-2025-3365","journal-title":"Blood"},{"key":"7191_CR38","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1056\/NEJMoa2406526","volume":"391","author":"C Roddie","year":"2024","unstructured":"Roddie C, Sandhu KS, Tholouli E et al (2024) Obecabtagene Autoleucel in Adults with B-Cell Acute Lymphoblastic Leukemia. N Engl J Med 391:2219\u20132230. https:\/\/doi.org\/10.1056\/NEJMoa2406526","journal-title":"N Engl J Med"},{"key":"7191_CR39","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1182\/bloodadvances.2024014182","volume":"9","author":"Y Wang","year":"2025","unstructured":"Wang Y, Lv L, Song Y et al (2025) Inaticabtagene autoleucel in adult relapsed or refractory B-cell acute lymphoblastic leukemia. Blood Adv 9:836\u2013843. https:\/\/doi.org\/10.1182\/bloodadvances.2024014182","journal-title":"Blood Adv"},{"key":"7191_CR40","doi-asserted-by":"publisher","first-page":"2173","DOI":"10.1182\/blood.2021012727","volume":"139","author":"AB Leahy","year":"2022","unstructured":"Leahy AB, Devine KJ, Li Y et al (2022) Impact of high-risk cytogenetics on outcomes for children and young adults receiving CD19-directed CAR T-cell therapy. Blood 139:2173\u20132185. https:\/\/doi.org\/10.1182\/blood.2021012727","journal-title":"Blood"},{"key":"7191_CR41","doi-asserted-by":"publisher","first-page":"5249","DOI":"10.1182\/bloodadvances.2025015881","volume":"9","author":"S John","year":"2025","unstructured":"John S, Curran KJ, Hall EM et al (2025) Real-world data for tisagenlecleucel in patients with R\/R B-ALL: subgroup analyses from the CIBMTR registry. Blood Adv 9:5249\u20135262. https:\/\/doi.org\/10.1182\/bloodadvances.2025015881","journal-title":"Blood Adv"},{"key":"7191_CR42","doi-asserted-by":"publisher","first-page":"2406","DOI":"10.1182\/blood-2015-08-665547","volume":"127","author":"R Gardner","year":"2016","unstructured":"Gardner R, Wu D, Cherian S et al (2016) Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy. Blood 127:2406\u20132410. https:\/\/doi.org\/10.1182\/blood-2015-08-665547","journal-title":"Blood"},{"key":"7191_CR43","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.1158\/2159-8290.CD-20-0242","volume":"11","author":"MA Nix","year":"2021","unstructured":"Nix MA, Mandal K, Geng H et al (2021) Surface Proteomics Reveals CD72 as a Target for In Vitro-Evolved Nanobody-Based CAR-T Cells in KMT2A\/MLL1-Rearranged B-ALL. Cancer Discov 11:2032\u20132049. https:\/\/doi.org\/10.1158\/2159-8290.CD-20-0242","journal-title":"Cancer Discov"},{"key":"7191_CR44","doi-asserted-by":"publisher","unstructured":"Ren H, Elliott N, Lye B et al (2025) Off-the-shelf dual CAR-iNKT cell immunotherapy eradicates medullary and leptomeningeal high-risk KMT2A-rearranged leukemia. Blood J Blood 2025029302. https:\/\/doi.org\/10.1182\/blood.2025029302","DOI":"10.1182\/blood.2025029302"},{"key":"7191_CR45","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmb.2024.168453","volume":"436","author":"HT Van","year":"2024","unstructured":"Van HT, Xie G, Dong P et al (2024) KMT2 family of H3K4 methyltransferases: enzymatic activity-dependent and -independent functions. J Mol Biol 436:168453. https:\/\/doi.org\/10.1016\/j.jmb.2024.168453","journal-title":"J Mol Biol"},{"key":"7191_CR46","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.bcp.2017.09.007","volume":"147","author":"D Steinhilber","year":"2018","unstructured":"Steinhilber D, Marschalek R (2018) How to effectively treat acute leukemia patients bearing MLL-rearrangements ? Biochem Pharmacol 147:183\u2013190. https:\/\/doi.org\/10.1016\/j.bcp.2017.09.007","journal-title":"Biochem Pharmacol"},{"key":"7191_CR47","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1038\/s41556-023-01270-1","volume":"25","author":"L Sha","year":"2023","unstructured":"Sha L, Yang Z, An S et al (2023) Non-canonical MLL1 activity regulates centromeric phase separation and genome stability. Nat Cell Biol 25:1637\u20131649. https:\/\/doi.org\/10.1038\/s41556-023-01270-1","journal-title":"Nat Cell Biol"},{"key":"7191_CR48","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1038\/nature09350","volume":"467","author":"H Liu","year":"2010","unstructured":"Liu H, Takeda S, Kumar R et al (2010) Phosphorylation of MLL by ATR is required for execution of mammalian S-phase checkpoint. Nature 467:343\u2013346. https:\/\/doi.org\/10.1038\/nature09350","journal-title":"Nature"},{"key":"7191_CR49","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/j.devcel.2017.05.023","volume":"41","author":"A Ali","year":"2017","unstructured":"Ali A, Veeranki SN, Chinchole A, Tyagi S (2017) MLL\/WDR5 Complex Regulates Kif2A Localization to Ensure Chromosome Congression and Proper Spindle Assembly during Mitosis. Dev Cell 41:605\u2013622e7. https:\/\/doi.org\/10.1016\/j.devcel.2017.05.023","journal-title":"Dev Cell"},{"key":"7191_CR50","doi-asserted-by":"publisher","first-page":"15751","DOI":"10.1073\/pnas.1111498108","volume":"108","author":"D Biswas","year":"2011","unstructured":"Biswas D, Milne TA, Basrur V et al (2011) Function of leukemogenic mixed lineage leukemia 1 (MLL) fusion proteins through distinct partner protein complexes. Proc Natl Acad Sci USA 108:15751\u201315756. https:\/\/doi.org\/10.1073\/pnas.1111498108","journal-title":"Proc Natl Acad Sci USA"},{"key":"7191_CR51","doi-asserted-by":"publisher","first-page":"5695","DOI":"10.1038\/sj.onc.1204639","volume":"20","author":"PM Ayton","year":"2001","unstructured":"Ayton PM, Cleary ML (2001) Molecular mechanisms of leukemogenesis mediated by MLL fusion proteins. Oncogene 20:5695\u20135707. https:\/\/doi.org\/10.1038\/sj.onc.1204639","journal-title":"Oncogene"},{"key":"7191_CR52","doi-asserted-by":"publisher","first-page":"6199","DOI":"10.1158\/0008-5472.CAN-07-6514","volume":"68","author":"J Chen","year":"2008","unstructured":"Chen J, Santillan DA, Koonce M et al (2008) Loss of MLL PHD Finger 3 Is Necessary for MLL-ENL\u2013Induced Hematopoietic Stem Cell Immortalization. Cancer Res 68:6199\u20136207. https:\/\/doi.org\/10.1158\/0008-5472.CAN-07-6514","journal-title":"Cancer Res"},{"key":"7191_CR53","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1038\/leu.2009.177","volume":"23","author":"R Ono","year":"2009","unstructured":"Ono R, Kumagai H, Nakajima H et al (2009) Mixed-lineage-leukemia (MLL) fusion protein collaborates with Ras to induce acute leukemia through aberrant Hox expression and Raf activation. Leukemia 23:2197\u20132209. https:\/\/doi.org\/10.1038\/leu.2009.177","journal-title":"Leukemia"},{"key":"7191_CR54","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1016\/j.exphem.2015.05.012","volume":"43","author":"C-W Chen","year":"2015","unstructured":"Chen C-W, Armstrong SA (2015) Targeting DOT1L and HOX gene expression in MLL-rearranged leukemia and beyond. Exp Hematol 43:673\u2013684. https:\/\/doi.org\/10.1016\/j.exphem.2015.05.012","journal-title":"Exp Hematol"},{"key":"7191_CR55","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1038\/nchembio.773","volume":"8","author":"J Grembecka","year":"2012","unstructured":"Grembecka J, He S, Shi A et al (2012) Menin-MLL inhibitors reverse oncogenic activity of MLL fusion proteins in leukemia. Nat Chem Biol 8:277\u2013284. https:\/\/doi.org\/10.1038\/nchembio.773","journal-title":"Nat Chem Biol"},{"key":"7191_CR56","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1016\/j.ccell.2019.11.001","volume":"36","author":"AV Krivtsov","year":"2019","unstructured":"Krivtsov AV, Evans K, Gadrey JY et al (2019) A Menin-MLL Inhibitor Induces Specific Chromatin Changes and Eradicates Disease in Models of MLL-Rearranged Leukemia. Cancer Cell 36:660\u2013673e11. https:\/\/doi.org\/10.1016\/j.ccell.2019.11.001","journal-title":"Cancer Cell"},{"key":"7191_CR57","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/j.ccell.2015.02.016","volume":"27","author":"D Borkin","year":"2015","unstructured":"Borkin D, He S, Miao H et al (2015) Pharmacologic inhibition of the Menin-MLL interaction blocks progression of MLL leukemia in vivo. Cancer Cell 27:589\u2013602. https:\/\/doi.org\/10.1016\/j.ccell.2015.02.016","journal-title":"Cancer Cell"},{"key":"7191_CR58","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1007\/s40265-025-02161-5","volume":"85","author":"YY Syed","year":"2025","unstructured":"Syed YY (2025) Revumenib: First Approval. Drugs 85:577\u2013583. https:\/\/doi.org\/10.1007\/s40265-025-02161-5","journal-title":"Drugs"},{"key":"7191_CR59","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1158\/2643-3230.BCD-24-0212","volume":"6","author":"GC Issa","year":"2025","unstructured":"Issa GC, Cai SF, Bataller A et al (2025) Combination Strategies with Menin Inhibitors for Acute Leukemia. Blood Cancer Discovery 6:547\u2013560. https:\/\/doi.org\/10.1158\/2643-3230.BCD-24-0212","journal-title":"Blood Cancer Discovery"},{"key":"7191_CR60","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/s40164-025-00668-x","volume":"14","author":"J Sun","year":"2025","unstructured":"Sun J, Yu W, Zhang X (2025) MENIN inhibitor-based therapy in acute leukemia: latest updates from the 2024 ASH annual meeting. Exp Hematol Oncol 14:78. https:\/\/doi.org\/10.1186\/s40164-025-00668-x","journal-title":"Exp Hematol Oncol"},{"key":"7191_CR61","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1038\/s41586-023-05812-3","volume":"615","author":"GC Issa","year":"2023","unstructured":"Issa GC, Aldoss I, DiPersio J et al (2023) The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia. Nature 615:920\u2013924. https:\/\/doi.org\/10.1038\/s41586-023-05812-3","journal-title":"Nature"},{"key":"7191_CR62","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1200\/JCO.24.00826","volume":"43","author":"GC Issa","year":"2025","unstructured":"Issa GC, Aldoss I, Thirman MJ et al (2025) Menin Inhibition With Revumenib for KMT2A-Rearranged Relapsed or Refractory Acute Leukemia (AUGMENT-101). JCO 43:75\u201384. https:\/\/doi.org\/10.1200\/JCO.24.00826","journal-title":"JCO"},{"key":"7191_CR63","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1182\/blood-2024-194384","volume":"144","author":"I Aldoss","year":"2024","unstructured":"Aldoss I, Issa GC, Blachly JS et al (2024) Updated Results and Longer Follow-up from the AUGMENT-101 Phase 2 Study of Revumenib in All Patients with Relapsed or Refractory (R\/R) KMT2Ar Acute Leukemia. Blood 144:211\u2013211. https:\/\/doi.org\/10.1182\/blood-2024-194384","journal-title":"Blood"},{"key":"7191_CR64","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1182\/blood-2025-1001","volume":"146","author":"I Aldoss","year":"2025","unstructured":"Aldoss I, Issa G, Blachly J et al (2025) Revumenib for patients with relapsed or refractory (R\/R) KMT2Ar acute leukemia: outcomes by leukemia type in the phase 2 AUGMENT-101 study. Blood 146:1001. https:\/\/doi.org\/10.1182\/blood-2025-1001","journal-title":"Blood"},{"key":"7191_CR65","unstructured":"Neerav S, Guest E, Tasian SK Safety and activity of Revumenib in combination with fludarabine\/cytarabine (FLA) in patients with relapsed\/refractory acute leukemias"},{"key":"7191_CR66","doi-asserted-by":"publisher","first-page":"4265.3","DOI":"10.1182\/blood-2024-204583","volume":"144","author":"E Salzer","year":"2024","unstructured":"Salzer E, Stutterheim J, Cuglievan B et al (2024) APAL2020K\/ITCC-101: a phase I trial of the menin inhibitor ziftomenib in combination with chemotherapy in children with relapsed\/refractory KMT2A-rearranged, NUP98-rearranged, or NPM1-mutant acute leukemias. Blood 144:4265.3. https:\/\/doi.org\/10.1182\/blood-2024-204583","journal-title":"Blood"},{"key":"7191_CR67","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1182\/blood-2024-207106","volume":"144","author":"E Searle","year":"2024","unstructured":"Searle E, Recher C, Abdul-Hay M et al (2024) Bleximenib Dose Optimization and Determination of RP2D from a Phase 1 Study in Relapsed\/Refractory Acute Leukemia Patients with KMT2A and NPM1 Alterations. Blood 144:212\u2013212. https:\/\/doi.org\/10.1182\/blood-2024-207106","journal-title":"Blood"},{"key":"7191_CR68","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1182\/blood-2024-194827","volume":"144","author":"JF Zeidner","year":"2024","unstructured":"Zeidner JF, Yuda J, Watts JM et al (2024) Phase 1 Results: First-in-Human Phase 1\/2 Study of the Menin-MLL Inhibitor Enzomenib (DSP-5336) in Patients with Relapsed or Refractory Acute Leukemia. Blood 144:213\u2013213. https:\/\/doi.org\/10.1182\/blood-2024-194827","journal-title":"Blood"},{"key":"7191_CR69","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1182\/blood-2025-763","volume":"146","author":"N Daver","year":"2025","unstructured":"Daver N, Zeidner J, Watts J et al (2025) Monotherapy update from Phase 1 portion in Phase1\/2 trial of the menin-MLL inhibitor enzomenib (DSP-5336) in patients with relapsed or refractory acute leukemia. Blood 146:763. https:\/\/doi.org\/10.1182\/blood-2025-763","journal-title":"Blood"},{"key":"7191_CR70","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1038\/s41586-023-05755-9","volume":"615","author":"F Perner","year":"2023","unstructured":"Perner F, Stein EM, Wenge DV et al (2023) MEN1 mutations mediate clinical resistance to menin inhibition. Nature 615:913\u2013919. https:\/\/doi.org\/10.1038\/s41586-023-05755-9","journal-title":"Nature"},{"key":"7191_CR71","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1182\/blood.2024025760","volume":"144","author":"CA Heckman","year":"2024","unstructured":"Heckman CA (2024) A menin-KMT2A inhibitor to overcome resistance. Blood 144:1139\u20131140. https:\/\/doi.org\/10.1182\/blood.2024025760","journal-title":"Blood"},{"key":"7191_CR72","doi-asserted-by":"publisher","first-page":"6020","DOI":"10.3390\/ijms25116020","volume":"25","author":"FRS Adriaanse","year":"2024","unstructured":"Adriaanse FRS, Schneider P, Arentsen-Peters STCJM et al (2024) Distinct Responses to Menin Inhibition and Synergy with DOT1L Inhibition in KMT2A-Rearranged Acute Lymphoblastic and Myeloid Leukemia. IJMS 25:6020. https:\/\/doi.org\/10.3390\/ijms25116020","journal-title":"IJMS"},{"key":"7191_CR73","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1182\/blood.2024026232","volume":"145","author":"G Huls","year":"2025","unstructured":"Huls G, Woolthuis CM, Schuringa JJ (2025) Menin inhibitors in the treatment of acute myeloid leukemia. Blood 145:561\u2013566. https:\/\/doi.org\/10.1182\/blood.2024026232","journal-title":"Blood"},{"key":"7191_CR74","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-018-0607-3","volume":"11","author":"C Roolf","year":"2018","unstructured":"Roolf C, Richter A, Konkolefski C et al (2018) Decitabine demonstrates antileukemic activity in B cell precursor acute lymphoblastic leukemia with MLL rearrangements. J Hematol Oncol 11:62. https:\/\/doi.org\/10.1186\/s13045-018-0607-3","journal-title":"J Hematol Oncol"},{"key":"7191_CR75","doi-asserted-by":"publisher","DOI":"10.3390\/ijms252111740","volume":"25","author":"A Rossi","year":"2024","unstructured":"Rossi A, Zacchi F, Reni A et al (2024) Progresses and pitfalls of epigenetics in solid tumors clinical trials. Int J Mol Sci 25:11740. https:\/\/doi.org\/10.3390\/ijms252111740","journal-title":"Int J Mol Sci"},{"key":"7191_CR76","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1038\/nrg2005","volume":"8","author":"M Esteller","year":"2007","unstructured":"Esteller M (2007) Cancer epigenomics: DNA methylomes and histone-modification maps. Nat Rev Genet 8:286\u2013298. https:\/\/doi.org\/10.1038\/nrg2005","journal-title":"Nat Rev Genet"},{"key":"7191_CR77","doi-asserted-by":"publisher","first-page":"2348","DOI":"10.1158\/1078-0432.CCR-14-1290","volume":"21","author":"MC Stubbs","year":"2015","unstructured":"Stubbs MC, Kim W, Bariteau M et al (2015) Selective Inhibition of HDAC1 and HDAC2 as a Potential Therapeutic Option for B-ALL. Clin Cancer Res 21:2348\u20132358. https:\/\/doi.org\/10.1158\/1078-0432.CCR-14-1290","journal-title":"Clin Cancer Res"},{"key":"7191_CR78","doi-asserted-by":"publisher","first-page":"e127","DOI":"10.1038\/oncsis.2014.39","volume":"3","author":"K Ahmad","year":"2014","unstructured":"Ahmad K, Katryniok C, Scholz B et al (2014) Inhibition of class I HDACs abrogates the dominant effect of MLL-AF4 by activation of wild-type MLL. Oncogenesis 3:e127\u2013e127. https:\/\/doi.org\/10.1038\/oncsis.2014.39","journal-title":"Oncogenesis"},{"key":"7191_CR79","doi-asserted-by":"publisher","DOI":"10.1038\/s42003-024-06916-w","volume":"7","author":"TCAI Verbeek","year":"2024","unstructured":"Verbeek TCAI, Vrenken KS, Arentsen-Peters STCJM et al (2024) Selective inhibition of HDAC class IIA as therapeutic intervention for KMT2A-rearranged acute lymphoblastic leukemia. Commun Biol 7:1257. https:\/\/doi.org\/10.1038\/s42003-024-06916-w","journal-title":"Commun Biol"},{"key":"7191_CR80","doi-asserted-by":"publisher","first-page":"2574","DOI":"10.1182\/blood.2024026598","volume":"145","author":"G Egan","year":"2025","unstructured":"Egan G, Tasian SK (2025) Precision medicine for high-risk gene fusions in pediatric AML: a focus on KMT2A, NUP98, and GLIS2 rearrangements. Blood 145:2574\u20132586. https:\/\/doi.org\/10.1182\/blood.2024026598","journal-title":"Blood"},{"key":"7191_CR81","doi-asserted-by":"publisher","first-page":"2661","DOI":"10.1182\/blood-2017-12-818948","volume":"131","author":"EM Stein","year":"2018","unstructured":"Stein EM, Garcia-Manero G, Rizzieri DA et al (2018) The DOT1L inhibitor pinometostat reduces H3K79 methylation and has modest clinical activity in adult acute leukemia. Blood 131:2661\u20132669. https:\/\/doi.org\/10.1182\/blood-2017-12-818948","journal-title":"Blood"},{"key":"7191_CR82","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nrm2308","volume":"9","author":"RJ Youle","year":"2008","unstructured":"Youle RJ, Strasser A (2008) The BCL-2 protein family: opposing activities that mediate cell death. Nat Rev Mol Cell Biol 9:47\u201359. https:\/\/doi.org\/10.1038\/nrm2308","journal-title":"Nat Rev Mol Cell Biol"},{"key":"7191_CR83","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000912","volume":"7","author":"AH Wei","year":"2023","unstructured":"Wei AH, Roberts AW (2023) BCL2 inhibition: a new paradigm for the treatment of AML and beyond. HemaSphere 7:e912. https:\/\/doi.org\/10.1097\/HS9.0000000000000912","journal-title":"HemaSphere"},{"key":"7191_CR84","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1158\/2159-8290.CD-14-0353","volume":"4","author":"TN Chonghaile","year":"2014","unstructured":"Chonghaile TN, Roderick JE, Glenfield C et al (2014) Maturation Stage of T-cell Acute Lymphoblastic Leukemia Determines BCL-2 versus BCL-XL Dependence and Sensitivity to ABT-199. Cancer Discov 4:1074\u20131087. https:\/\/doi.org\/10.1158\/2159-8290.CD-14-0353","journal-title":"Cancer Discov"},{"key":"7191_CR85","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1111\/j.1365-2141.2008.07100.x","volume":"141","author":"BW Robinson","year":"2008","unstructured":"Robinson BW, Behling KC, Gupta M et al (2008) Abundant anti-apoptotic BCL\u20102 is a molecular target in leukaemias with t(4;11) translocation. Br J Haematol 141:827\u2013839. https:\/\/doi.org\/10.1111\/j.1365-2141.2008.07100.x","journal-title":"Br J Haematol"},{"key":"7191_CR86","doi-asserted-by":"publisher","first-page":"2715","DOI":"10.1016\/j.celrep.2015.12.003","volume":"13","author":"JM Benito","year":"2015","unstructured":"Benito JM, Godfrey L, Kojima K et al (2015) MLL-Rearranged Acute Lymphoblastic Leukemias Activate BCL-2 through H3K79 Methylation and Are Sensitive to the BCL-2-Specific Antagonist ABT-199. Cell Rep 13:2715\u20132727. https:\/\/doi.org\/10.1016\/j.celrep.2015.12.003","journal-title":"Cell Rep"},{"key":"7191_CR87","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1182\/bloodadvances.2023012231","volume":"8","author":"NJ Short","year":"2024","unstructured":"Short NJ, Jabbour E, Jain N et al (2024) A phase 1\/2 study of mini-hyper-CVD plus venetoclax in patients with relapsed\/refractory acute lymphoblastic leukemia. Blood Adv 8:909\u2013915. https:\/\/doi.org\/10.1182\/bloodadvances.2023012231","journal-title":"Blood Adv"},{"key":"7191_CR88","doi-asserted-by":"publisher","first-page":"14835","DOI":"10.18632\/oncotarget.11730","volume":"8","author":"M Kerstjens","year":"2017","unstructured":"Kerstjens M, Driessen EMC, Willekes M et al (2017) MEK inhibition is a promising therapeutic strategy for MLL-rearranged infant acute lymphoblastic leukemia patients carrying RAS mutations. Oncotarget 8:14835\u201314846. https:\/\/doi.org\/10.18632\/oncotarget.11730","journal-title":"Oncotarget"},{"key":"7191_CR89","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1038\/sj.leu.2404277","volume":"20","author":"P Brown","year":"2006","unstructured":"Brown P, Levis M, McIntyre E et al (2006) Combinations of the FLT3 inhibitor CEP-701 and chemotherapy synergistically kill infant and childhood MLL-rearranged ALL cells in a sequence-dependent manner. Leukemia 20:1368\u20131376. https:\/\/doi.org\/10.1038\/sj.leu.2404277","journal-title":"Leukemia"},{"key":"7191_CR90","doi-asserted-by":"publisher","first-page":"2484","DOI":"10.1182\/blood-2004-09-3667","volume":"106","author":"RW Stam","year":"2005","unstructured":"Stam RW (2005) Targeting FLT3 in primary MLL-gene-rearranged infant acute lymphoblastic leukemia. Blood 106:2484\u20132490. https:\/\/doi.org\/10.1182\/blood-2004-09-3667","journal-title":"Blood"},{"key":"7191_CR91","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1038\/s41375-021-01177-6","volume":"35","author":"PA Brown","year":"2021","unstructured":"Brown PA, Kairalla JA, Hilden JM et al (2021) FLT3 inhibitor lestaurtinib plus chemotherapy for newly diagnosed KMT2A-rearranged infant acute lymphoblastic leukemia: Children\u2019s Oncology Group trial AALL0631. Leukemia 35:1279\u20131290. https:\/\/doi.org\/10.1038\/s41375-021-01177-6","journal-title":"Leukemia"},{"key":"7191_CR92","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/j.canlet.2019.11.005","volume":"469","author":"MO Forgione","year":"2020","unstructured":"Forgione MO, McClure BJ, Eadie LN et al (2020) KMT2A rearranged acute lymphoblastic leukaemia: Unravelling the genomic complexity and heterogeneity of this high-risk disease. Cancer Lett 469:410\u2013418. https:\/\/doi.org\/10.1016\/j.canlet.2019.11.005","journal-title":"Cancer Lett"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-026-07191-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-07191-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-07191-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T09:42:55Z","timestamp":1789465375000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-026-07191-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,24]]},"references-count":92,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["7191"],"URL":"https:\/\/doi.org\/10.1007\/s00277-026-07191-x","relation":{},"ISSN":["1432-0584"],"issn-type":[{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,24]]},"assertion":[{"value":"7 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"369"}}